Cargando…

Inspiratory Flows and Volumes in Subjects with Cystic Fibrosis Using a New Dry Powder Inhaler Device

INTRODUCTION: Drug inhalation via a dry-powder inhaler (DPI) is a convenient, time efficient alternative to nebulizers in the treatment of cystic fibrosis (CF). Efficient drug administration via DPIs depends on the device resistance and adequate (≥ 45L/min) inspiratory flows and volumes generated by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elkins, Mark R., Robinson, Philip, Anderson, Sandra D., Perry, Clare P., Daviskas, Evangelia, Charlton, Brett
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933773/ https://www.ncbi.nlm.nih.gov/pubmed/24570763 http://dx.doi.org/10.2174/1874306401408010001

Ejemplares similares

Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device
por: Elkins, Mark R., et al.
Publicado: (2014)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates
por: Clark, Andrew R., et al.
Publicado: (2020)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices
por: Hira, Daiki, et al.
Publicado: (2018)

Inappropriate Peak Inspiratory Flow Rate with Dry Powder Inhaler in Chronic Obstructive Pulmonary Disease
por: Chen, Shih-Yu, et al.
Publicado: (2020)

Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD
por: Chetta, Alfredo, et al.
Publicado: (2021)

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
por: Wilson, Robert, et al.
Publicado: (2013)

Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial hypertension using AOS™ dry powder inhaler device
por: Sahay, Sandeep, et al.
Publicado: (2021)

The effect of inspiratory parameters after two separate inhalations on the dose emission of theophylline from low and high resistance dry powder inhalers
por: Abadelah, Mohamad, et al.
Publicado: (2020)

Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension
por: Faria-Urbina, Mariana, et al.
Publicado: (2021)

Peak inspiratory flow in children and adolescents with asthma using dry powder inhalers: a cross-sectional study
por: da Silva, Caroline Palácio, et al.
Publicado: (2021)

Lung Function Can Predict the Expected Inspiratory Airflow Rate through Dry Powder Inhalers in Asthmatic Adolescents
por: Dal Negro, Roberto Walter, et al.
Publicado: (2022)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study
por: Martínez-García, Miguel Ángel, et al.
Publicado: (2020)

Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters
por: Malmberg, L Pekka, et al.
Publicado: (2010)

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
por: Schuster, Antje, et al.
Publicado: (2013)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Optimising inhaled mannitol for cystic fibrosis in an adult population
por: Flume, Patrick A., et al.
Publicado: (2015)

The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline
por: Brannan, John D, et al.
Publicado: (2005)

Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis
por: Lu, Peng, et al.
Publicado: (2022)

Effects of treadmill exercise versus Flutter® on respiratory flow and sputum properties in adults with cystic fibrosis: a randomised, controlled, cross-over trial
por: Dwyer, Tiffany J., et al.
Publicado: (2017)

Inspiration for the Future: The Role of Inspiratory Muscle Training in Cystic Fibrosis
por: Shei, Ren-Jay, et al.
Publicado: (2019)

Prevalence and Associated Factors of Suboptimal Daily Peak Inspiratory Flow and Technique Misuse of Dry Powder Inhalers in Outpatients with Stable Chronic Airway Diseases
por: Ding, Nan, et al.
Publicado: (2021)

Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD
por: Jõgi, Rain, et al.
Publicado: (2021)

Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations
por: Shepard, Kimberly B., et al.
Publicado: (2022)

Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study
por: van Koningsbruggen-Rietschel, Silke, et al.
Publicado: (2020)

Understanding the Importance of Capsules in Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2021)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers
por: Lexmond, Anne J., et al.
Publicado: (2014)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Inhaled therapy in cystic fibrosis: agents, devices and regimens
por: Agent, Penny, et al.
Publicado: (2015)

Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study
por: Stass, Heino, et al.
Publicado: (2013)

Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
por: Chennakesavulu, S., et al.
Publicado: (2018)

Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
por: Saha, Tushar, et al.
Publicado: (2022)

The Diskus™: a review of its position among dry powder inhaler devices
por: Chrystyn, H
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_76un5d36egm4ja3hlbo2t5ersk